|
Published by: SMI Publishing, Ltd
Published: Jun. 28, 2006
Table of Contents
- Day 1
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Philip Gerrard, Director, Behavioural Neuroscience, GlaxoSmithKline.
- 9.10 DETAILED R&D THEMES BY THERAPY AREAS AND DRUG MECHANISMS
- Review of mechanisms involved in depression and anxiety disorders: towards novel therapies
- Modulation of central monoamine systems
- Dysfunction of the hypothalamic-pituitary-adrenal ( HPA) axis
- Neuronal plasticity
- Inflammatory mediators
- Future perspectives
- Dr Philip Gerrard, Director, Behavioural Neuroscience, GlaxoSmithKline.
- 9.50 INNOVATIVE APPROACHES TO DECIPHERING THE CAUSES OF DEPRESSION AND ANXIETY
- Identifying potential targets and techniques to elucidate prevailing mood disorders
- Decoding depression - from classical monaminergics to novel antidepressant mechanisms
- Linking behavioural biology and clinical psychopharmacology: Can CNS biomarkers help out?
- Developing relevant in vivo assays and technologies to aid translational studies
- Collaboration - is outsourcing the key to success
- Dr Pim Drinkenburg, Head, CNS Center of Expertise - Biomonitoring , Johnson & Johnson Pharmaceutical Research & Development.
- 10.30 Morning Coffee
- 11.00 MODULATION OF NEURONAL NICOTINIC RECEPTORS (NNRs) IN DEPRESSION AND ANXIETY
- A new therapeutic approach
- Smoking and depression are linked clinically. Can a new radical treatment effect both disorders?
- All antidepressants are antagonists at NNRs
- Introducing mecamylamine as an effective add-on treatment to patients who fail to respond to fluoxetine
- Presenting TC-2216 a selective NNR antagonist with preclinical features of an antidepressant/anti-anxiety agent
- Potential for TC-2216 as an anti-smoking therapy
- Dr Geoffrey Dunbar, Senior Vice President, Clinical Development & RA, Targacept Inc.
- 11.40 THE RELEVANCE OF CLINICAL TRIALS IN DEPRESSION AND ANXIETY
- Practical advice for practical people
- Controlled vs naturalistic studies
- Efficacy vs effectiveness
- Endpoints - which should be primary?
- Interpreting meta-analysis
- Beyond tolerability
- Dr Alan Lenox-Smith, Senior Medical Advisor, Wyeth.
- 12.20 Networking Lunch
- 1.50 GABA RECEPTORS: DRUG TARGETS IN AN AGE OF ANXIETY?
- Integrating data from molecules, mice and man to develop novel anxioselectives
- The role of GABAergic pathways in anxiety disorders
- Hunting for anxioselective agents: what have we learnt from transgenic mice?
- Do currently prescribed anxiolytics short change patients?
- Studies with Ocinaplon, a novel GABAA receptor modulator, in GAD
- Dr Phil Skolnick, Senior VP, Research & CSO, DOV Pharmaceutical, Inc..
- 2.30 WHY GOOD DRUGS GO BAD?
- Translational issues related to efficacy in CNS new drug discovery
- Criteria for moving to the clinic
- Surrogate markers and proof of concept
- Key elements of efficacy study design
- Dose finding
- Target investigational populations
- Dr David Michelson, Executive Director for Neuroscience Medical Research, Lilly Research Laboratories.
- Dr Eduardo Dunayevich, Medical Advisor, Eli Lilly & Co.
- 3.10 Afternoon Tea
- 3.40 CASE STUDY: ABILIFY - FROM BENCH TO BEDSIDE
- Is this the new blockbuster for treating psychotic disorders?
- Benefits of partial receptor agonism
- Advantages of multiple mechanisms
- Widespread applications of atypical antipsychotics
- Looking ahead: Harnessing genomics to create new drug candidates
- Dr C. Anthony Altar, President & Chief Scientific Officer, Pychiatric Genomics Inc.
- Dr C. Anthony Altar, President & Chief Scientific Officer, Pychiatric Genomics Inc.
- 4.20 WHAT LIES AHEAD FOR ANTIDEPRESSANT THERAPY?
- An interactive depression & anxiety “Question Time”
- Dr Pim Drinkenburg, Head, CNS Center of Expertise - Biomonitoring , Johnson & Johnson Pharmaceutical Research & Development.
- Dr Geoffrey Dunbar, Senior Vice President, Clinical Development & RA, Targacept Inc.
- Dr C. Anthony Altar, President & Chief Scientific Officer, Pychiatric Genomics Inc.
- Dr Philip Gerrard, Director, Behavioural Neuroscience, GlaxoSmithKline.
- Dr Phil Skolnick, Senior VP, Research & CSO, DOV Pharmaceutical, Inc..
- 5.00 Chairman’s Closing Remarks and Close of Day One
- Day 2
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Amir Kalali, Vice President, Medical & Scientific Services & Global Scientific Head CNS, Quintiles.
- 9.10 CRISIS AND OPPORTUNITY: CHALLENGES FACING CNS DRUG DEVELOPMENT IN 2006
- What are they and how can we overcome them?
- A review of issues facing all CNS drug developers currently
- Discussion of the dangers to the viability of CNS drug development
- Ideas on how we might overcome these challenges
- Dr Amir Kalali, Vice President, Medical & Scientific Services & Global Scientific Head CNS, Quintiles.
- 9.50 CAN PSYCHOPHARMACOGENOMICS ELIMINATE THE NEED FOR TRIAL AND ERROR TREATMENT
- Potential consequences for future drug development
- The quest for drug therapy in depression based on genetics.
- Identifying new genetic markers used to predict patient response
- Demonstrating pipeline benefits- rescuing Vilazodone.
- Dr Maria Athanasiou, Senior Project Manager, Genaissance Pharmaceuticals Incorported.
- 10.30 Morning Coffee
- 11.00 SHEDDING LIGHT ON THE PSYCHOPHARMACEUTICAL CONUNDRUM
- Recent advances in neuroimaging and the emergence of surrogate markers of drug action
- The history and limitations of classical psychopharmacological approaches to drug action
- Effects of psychotropic drugs on measures of emotional processing
- Surrogate markers of drug action on emotional circuitry
- Future prospects for understanding pathophysiology and facilitating drug development
- Dr Phillip Cowen, Head, Psychopharmacology Research Unit , Department of Psychiatry, University of Oxford.
- 11.40 ADDRESSING THE PHENOMENA OF HIGH PLACEBO RESPONSE RATES
- The role of the clinical rater in overcoming high placebo effect
- Baseline inflation
- Applied vs. passive rating skills
- The relationship of rater skills to assay sensitivity
- A strategy for enhancing and monitoring clinical rater performance in multi-site trials
- Using technology to improve results
- Dr Joshua Lipsitz, Assistant Clinical Professor, Department of Psychiatry, Columbia University , MedAvante, Inc.
- 12.20 Networking Lunch
- 2.00 ENLISTING HEALTHY SPECIMENS TO VERIFY TRIAL RESULTS
- Pharmacodynamic models of anxiety in healthy volunteer studies
- What information can healthy volunteer models provide to help accelerate clinical development programmes in anxiety?
- Can acute volunteer models reflect a chronic disease state?
- How successful are models at predicting the effects of compounds with novel mechanisms of action?
- Dr John Connell, Head, Clinical Pharmacodynamics, Medeval Limited.
- 2.40 VNS THERAPY FOR MOOD DISORDERS
- How to minimise the degenerative effects of depression?
- Examining the extent and prevalence of the problem
- Comorbidities
- Vagus Nerve Stimulation (VNS) therapy: mechanism of action in depression
- Main clinical trials of VNS in depression
- Dr Renata Van Woensel, Medical Science Liaison, Cyberonics Europe SA.
- 3.20 THE POTENTIAL FOR COMBINATION THERAPIES IN THE TREATMENT OF AFFECTIVE DISORDERS
- The characteristics and treatment of chronic depression
- Determining the extent and nature of the problem
- Do monotherapies offer the potential for effective treatment?
- What substrates are available adjunctive therapies to address?
- The current horizon for novel neurotherapeutics
- Will treatment of residual symptoms cut the risk of relapse?
- Dr Hugh Marston, Head, Neurobiology Section, Department of Pharmacology, Organon Labs Ltd..
- 4.00 Chairman’s Closing Remarks Followed by Afternoon Tea
- Close of Day Two
AbstractFollowing the success of our first event in 2003, SMi are proud to present their 2nd strategic forum on Depression and Anxiety to be held in London this June. We have invited key industry experts to explore the current and future opportunities within psychopharmacotherapy, namely the growing challenges of diagnosing and treating the spectrum of distinct disorders.
Register now to secure your place and join us in central London on 28th & 29th June 2006, to get the opportunity to meet some of the leading lights of the global psychopharmaceutical community as they share their insights and expertise.
Some of our confirmed speakers:
- Dr Phil Skolnick Senior Vice President, Research & Chief Scientific Officer, DOV Pharmaceuticals
- Dr Amir Kalali, Vice President, Medical & Scientific Services, Global Scientific Head, CNS Therapeutics, Quintiles
- Dr Phil Gerrard, Director, Behavioural Neuroscience, Psychiatry Centre of Excellence Drug Discovery, GlaxoSmithKline,
- Dr Pim Drinkenburg, Head, CNS Center of Expertise - Biomonitoring, Johnson & Johnson Pharmaceutical Research & Development
- Dr Hugh Marston, Head, Neurobiology Section, Department of Pharmacology, Organon Laboratories
- Professor Phillip Cowen, Head, Psychopharmacology Research Unit, Oxford University
- Kim Domela Kjøller, Director, Strategic Marketing Division, Lundbeck
- Dr Eduardo Dunayevich, Medical Advisor, Lilly Research Laboratories
SMi’s 2nd conference on Depression and Anxiety aims to uncover the latest clinical and commercial factors affecting the key industry players in the psychopharmaceuticals market. The conference will feature presentations from senior industry practitioners, leading academic researchers, and cutting edge bio-technical laboratories from around the world. These scientists have dedicated their careers to unravelling the mysteries of the novel factors found within psychiatric disease in order to to create the most innovative and effective treatments. Efforts to better treat schizophrenia, depression, anxiety, bipolar disease, psychosis, and related indications will be described. Strategies for bringing these new therapies to patients will also be addressed, with a focus on translational clinical research and development specially designed to combat these debilatating mood disorders.
This two day intensive forum will help you learn more about:
- THE PSYCHOPHARMACOTHERAPY MARKET: Review the latest offerings to emerge from the psychopharmaceutical drug development pipeline and what opportunities and obstacles lie ahead in this dynamic but increasingly hostile market
- MOOD DISORDERS: Consider the different indications found within the distinct disorder spectrum and the new therapeutic approaches currently being devised to combat unmet medical needs
- PSYCHOGENOMICS: Discover how genetics could provide the key to producing a truly individualised therapy system, and how the latest discoveries could help salvage previously doomed drug candidates
- TRANSLATIONAL ISSUES: Evaluate the latest technologies to be used in identifying relevant biomarkers and measurement scales overcoming the traditional obstacles inherent within the CNS clinical trial process
- COMBINATION THERAPIES: Appraise the recent advances in novel neurotherapeutic solutions and join the debate raging between pharmacotherapy and psychotherapy - what are the resulting long-term implications?
- STRATEGIC SOLUTIONS: Gain a unique insight into and a greater understanding of how big pharma approach the challenges faced by the psychopharmacological community
- INFORMAL INTERACTION: Take the opportunity to mingle with key thinkers, test their knowledge during an interactive panel discussion and benefit from their shared experien
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
